Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACHV Stock Forecast 2026-2027
$6.10
Current Price
$626.22M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ACHV Price Targets
+244.3%
To High Target of $21.00
+96.7%
To Median Target of $12.00
+47.5%
To Low Target of $9.00
ACHV Price Momentum
-6.4%
1 Week Change
+10.5%
1 Month Change
+121.8%
1 Year Change
+22.7%
Year-to-Date Change
-14.2%
From 52W High of $7.11
+157.4%
From 52W Low of $2.37
📊 TOP ANALYST CALLS
Did ACHV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Achieve Life Sciences is one of their latest high-conviction picks.
Latest ACHV Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ACHV has a bullish consensus with a median price target of $12.00 (ranging from $9.00 to $21.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $6.10, the median forecast implies a 96.7% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACHV Analyst Ratings
9
Buy
0
Hold
0
Sell
ACHV Price Target Range
Low
$9.00
Average
$12.00
High
$21.00
Current: $6.10
Latest ACHV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACHV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 22, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $12.00 |
| Apr 21, 2026 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Apr 16, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 25, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 25, 2025 | Citizens | Market Outperform | Initiates | $N/A | |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Nov 14, 2024 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Sep 27, 2024 | Raymond James | Gary Nachman | Strong Buy | Initiates | $20.00 |
| Aug 15, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| May 13, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| Apr 17, 2024 | JonesTrading | Buy | Initiates | $N/A | |
| Apr 1, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Mar 5, 2024 | Lake Street | Buy | Maintains | $N/A | |
| Dec 12, 2023 | Oppenheimer | Outperform | Maintains | $N/A | |
| Jun 1, 2023 | Lake Street | Buy | Maintains | $N/A | |
| May 31, 2023 | Lake Street | Buy | Maintains | $N/A | |
| May 10, 2023 | Lake Street | Buy | Maintains | $N/A | |
| Mar 17, 2023 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Nov 16, 2022 | Maxim Group | Buy | Maintains | $N/A | |
| Oct 4, 2021 | Alliance Global Partners | Buy | Initiates | $N/A |
Achieve Life Sciences Inc (ACHV) Competitors
The following stocks are similar to Achieve Life Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ACHV
Achieve Life Sciences
mkt cap
627.25M
Achieve Life Sciences Inc (ACHV) Financial Data
Achieve Life Sciences Inc has a market capitalization of $626.22M with a P/E ratio of -5.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -496.1%.
Valuation Metrics
Market Cap
$626.22M
Enterprise Value
$611.90M
P/E Ratio
-5.0x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+4.7%
Current Ratio
2.6x
Debt/Equity
140.0x
ROE
-496.1%
ROA
-108.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Achieve Life Sciences Inc (ACHV) Business Model
About Achieve Life Sciences Inc
What They Do
Develops treatments for nicotine addiction.
Business Model
The company focuses on developing and commercializing cytisinicline, a plant-based treatment aimed at reducing nicotine withdrawal symptoms and cravings. Achieve Life Sciences generates revenue through regulatory approvals, manufacturing partnerships, and potential sales of cytisinicline in key markets for smoking cessation and nicotine dependence.
Additional Information
As a late-stage specialty pharmaceutical company in the biotechnology sector, Achieve Life Sciences is dedicated to addressing a significant public health issue related to smoking and nicotine addiction, which is a leading cause of preventable death globally. The company is headquartered in Bothell, Washington, and is committed to making cytisinicline widely available to individuals looking to quit nicotine products.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
25
CEO
Dr. Richard A. B. Stewart
Country
Canada
IPO Year
1995
Website
www.achievelifesciences.comAchieve Life Sciences Inc (ACHV) Latest News & Analysis
Latest News
Quick Summary
Achieve Life Sciences (NASDAQ: ACHV) held its 2026 Annual Meeting virtually, led by CEO Andrew Goldberg, with Chief Legal Officer Erik Atkisson acting as secretary.
Why It Matters
The virtual annual meeting indicates corporate governance and transparency, allowing investors to assess leadership and strategic direction, which can influence stock performance.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Achieve Life Sciences saw stock volatility but reached a new yearly high. Recent financing, supply chain shifts, and leadership changes improve its outlook, despite a non-drug-related CRL denial.
Why It Matters
Achieve Life Sciences shows resilience with stock recovery and positive developments, suggesting potential for growth and reduced risk, appealing to investors seeking opportunities.
Source: Seeking Alpha
Market Sentiment:
Positive
Achieve Life Sciences Joins Russell 2000® Index
15 days ago
Quick Summary
Achieve Life Sciences (Nasdaq: ACHV) has been added to the Russell 2000® Index effective June 26, 2026, and is also part of the Russell 3000® Index.
Why It Matters
Achieve Life Sciences' addition to the Russell 2000 Index may enhance its visibility and attract institutional investment, potentially boosting its stock price and liquidity.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Achieve Life Sciences' drug for treating nicotine dependence in adults has been rejected by the U.S. FDA, the company announced on Monday.
Why It Matters
Achieve Life Sciences' failed drug approval may negatively impact its stock price and investor confidence, signaling potential challenges in future product development and market competitiveness.
Source: Reuters
Market Sentiment:
Negative
FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned
22 days ago
Quick Summary
Achieve Life Sciences (NASDAQ:ACHV) received a Complete Response Letter from the FDA regarding its New Drug Application for cytisinicline, aimed at treating nicotine dependence.
Why It Matters
The FDA's Complete Response Letter signifies regulatory setbacks for Achieve Life Sciences, potentially delaying market entry for cytisinicline and impacting stock performance and investor sentiment.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Achieve Life Sciences received a Complete Response Letter from the FDA regarding its cytisinicline NDA, citing deficiencies at a third-party manufacturing facility, but no safety or efficacy issues were found.
Why It Matters
The CRL indicates regulatory hurdles for Achieve Life Sciences, potentially delaying product launch and impacting revenue projections, which could negatively affect stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACHV Stock
What is Achieve Life Sciences Inc's (ACHV) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Achieve Life Sciences Inc (ACHV) has a median price target of $12.00. The highest price target is $21.00 and the lowest is $9.00.
Is ACHV stock a good investment in 2027?
According to current analyst ratings, ACHV has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACHV stock?
Wall Street analysts predict ACHV stock could reach $12.00 in the next 12 months. This represents a 96.7% increase from the current price of $6.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Achieve Life Sciences Inc's business model?
The company focuses on developing and commercializing cytisinicline, a plant-based treatment aimed at reducing nicotine withdrawal symptoms and cravings. Achieve Life Sciences generates revenue through regulatory approvals, manufacturing partnerships, and potential sales of cytisinicline in key markets for smoking cessation and nicotine dependence.
What is the highest forecasted price for ACHV Achieve Life Sciences Inc?
The highest price target for ACHV is $21.00 from at , which represents a 244.3% increase from the current price of $6.10.
What is the lowest forecasted price for ACHV Achieve Life Sciences Inc?
The lowest price target for ACHV is $9.00 from at , which represents a 47.5% increase from the current price of $6.10.
What is the overall ACHV consensus from analysts for Achieve Life Sciences Inc?
The overall analyst consensus for ACHV is bullish. Out of 3 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are ACHV stock price projections?
Stock price projections, including those for Achieve Life Sciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 6:30 PM UTC